Open AccessSimultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts
Author(s) -
Antonella De Luca,
Claudio Arra,
Antonio D’Antonio,
Amelia Casamassimi,
Simona Losito,
Paola Ferraro,
Fortunato Ciardiello,
David Salomon,
Nicola Normanno
Publication year - 2000
Publication title -
oncogene
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.395
H-Index - 342
eISSN - 1476-5594
pISSN - 0950-9232
DOI - 10.1038/sj.onc.1203979
Subject(s) - biology , amphiregulin , epidermal growth factor , colorectal cancer , growth inhibition , in vivo , tgf alpha , cancer research , epidermal growth factor receptor , growth factor , medicine , cancer , in vitro , receptor , biochemistry , genetics
A majority of human colon carcinomas coexpress the epidermal growth factor (EGF)-related peptides transforming growth factor alpha (TGFalpha), amphiregulin (AR) and CRIPTO-1 (CR). We have synthesized novel, antisense mixed backbone oligonucleotides (AS MBOs) directed against TGFalpha, AR and CR. We screened the EGF-related AS MBOs for their ability to inhibit the anchorage independent growth of GEO human colon carcinoma cells. The MBOs that showed a high in vitro efficacy were then used for in vivo experiments. TGFalpha, AR and CR AS MBOs were able to inhibit the growth of GEO tumor xenografts in nude mice in a dose-dependent manner. Furthermore, the AS MBOs were able to specifically inhibit the expression of the target mRNAs and proteins in the tumor xenografts. A more significant tumor growth inhibition was observed when mice were treated with a combination of the three AS MBOs as compared to treatment with a single AS MBO. Finally, tumors from mice treated with TGFalpha, AR and CR AS MBOs showed a significant reduction of microvessel count, as compared with tumors from untreated mice or from mice treated with a single AS MBO. These data suggest that combinations of AS oligonucleotides directed against different growth factors might represent a novel, experimental therapy approach of colon carcinomas.